High-risk AMI patients had lower persistence with prescribed guideline-directed medications at 12 months compared to low-risk patients (45.9% vs 61.5%; adjusted RR 0.87, 95% CI 0.82-0.92).
Cohort (n=6,434)
Yes
Effect estimate: RR 0.87 (95% CI 0.82-0.92)
Absolute Event Rate: 45.9% vs 61.5%
BACKGROUND: Prior studies have demonstrated that patients with high-risk acute myocardial infarction (AMI) are less likely to receive guideline-directed medications during hospitalisation. It is unknown if this paradox persists following discharge. We aimed to assess if persistence with guideline-directed medications post discharge varies by patients' risk following AMI. METHODS: Data were analysed from two prospective, multicentre US AMI registries. The primary outcome was persistence with all prescribed guideline-directed medications (aspirin, β-blockers, statins, angiotensin-antagonists) at 1, 6 and 12 months post discharge. The association between risk and medication persistence post discharge was assessed using multivariable mixed-effect models. RESULTS: Among 6434 patients with AMI discharged home, 2824 were considered low-risk, 2014 intermediate-risk and 1596 high-risk for death based upon their Global Registry of Acute Coronary Event (GRACE) 6-month risk score. High-risk was associated with a lower likelihood of receiving all appropriate therapies at discharge compared with low-risk patients (relative risk (RR) 0.90; 95% CI 0.87 to 0.94). At 12 months, the rate of persistence with all prescribed therapies was 61.5%, 57.9% and 45.9% among low-risk, intermediate-risk and high-risk patients, respectively. After multivariable adjustment, high-risk was associated with lower persistence with all prescribed medications (RR 0.87; 95% CI 0.82 to 0.92) over follow-up. Similar associations were seen for individual medications. Over the 5 years of the study, persistence with prescribed therapies post discharge improved modestly among high-risk patients (RR 1.05; 95% CI 1.03 to 1.08 per year). CONCLUSIONS: High-risk patients with AMI have a lower likelihood of persistently taking prescribed medications post discharge as compared with low-risk patients. Continued efforts are needed to improve the use of guideline-directed medications in high-risk patients.
Shore et al. (Mon,) conducted a cohort in Acute myocardial infarction (n=6,434). High GRACE risk score vs. Low GRACE risk score was evaluated on Persistence with all prescribed guideline-directed medications at 1, 6 and 12 months post discharge (RR 0.87, 95% CI 0.82-0.92). High-risk AMI patients had lower persistence with prescribed guideline-directed medications at 12 months compared to low-risk patients (45.9% vs 61.5%; adjusted RR 0.87, 95% CI 0.82-0.92).